SAVA
Cassava Sciences, Inc. [SAVA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
SAVA Stock Summary
Top 10 Correlated Stocks
SAVA
In the News
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a clinical-stage biotechnology firm that develops drugs for Alzheimer's disease (AD).
Cassava Sciences' Data Once Again Misunderstood
Cassava Sciences' Simufilam staved off cognitive decline in mild Alzheimer's disease. The market reacted negatively anyway.
Cassava Sciences: Data For Mild Alzheimer's Disease Patients Provides Good Risk/Reward Profile
Cassava Sciences released data for over 200 patients in an open-label trial at 12 months. The mild AD subgroup performed unprecedentedly.
Why Is Cassava Sciences (SAVA) Stock Down 20% Today?
One of the biggest decliners in today's market is Cassava Sciences (NASDAQ: SAVA ). Shares of SAVA stock declined more than 20% at today's trough on the company's announced mid-stage results for its Alzheimer's treatment.
Cassava Plummets As 'Highly Desirable' Alzheimer's Results Don't Cut It With Investors
Cassava disappointed Tuesday with midstage results for its oral Alzheimer's treatment and SAVA stock plummeted by a double-digit percentage. The post Cassava Plummets As 'Highly Desirable' Alzheimer's Results Don't Cut It With Investors appeared first on Investor's Business Daily.
Is a Short Squeeze Coming in Cassava Sciences (SAVA) Stock?
Amid surging interest in a wide swath of meme stocks today, retail investors are once again seeing traction in trading unpopular names. That said, other companies many may not necessarily associate with the meme trade are also surging.
6 Favorite Biotech Bets For 2023
Biotechnology has often been among the most popular sectors in the MoneyShow Top Picks report, our annual survey of the nation's leading newsletter advisors. This year's report is no exception; here's a six-pack of favorite biotech ideas for the coming year.
Why Is Cassava Sciences (SAVA) Stock Up 10% Today?
The completion of part of an important study is pushing Cassava Sciences (NASDAQ: SAVA ) stock up today. This clinical-stage biotech company has been volatile this month but has overall performed well.
Cassava Sciences Stock's Bull Signal Has Never Been Wrong
The shares of Cassava Sciences Inc (NASDAQ:SAVA) are down 3.5% at $32.17 this afternoon, after the company announced a $50 million registered direct stock offering on Friday.
7 Stocks Rattled by Corporate Scandals and Shenanigans in 2022
High inflation and soaring interest rates have been the main factor behind the double-digit stock downturn so far this year, but alongside these macro factors, many stocks have plunged due to more company-specific issues—for example, corporate scandals. These scandals run the gamut, both in the type of scandal and the severity of the scandal.
SAVA Financial details
SAVA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -1.82 | -0.61 | -0.27 | -0.24 | -0.82 | |
| Operating cash flow per share | -1.26 | -0.45 | -0.14 | -0.21 | -0.77 | |
| Free cash flow per share | -1.26 | -0.45 | -0.15 | -0.22 | -1.33 | |
| Cash per share | 1.6 | 1.85 | 1.33 | 3.58 | 5.92 | |
| Book value per share | 1.48 | 1.84 | 1.27 | 3.53 | 6.44 | |
| Tangible book value per share | 1.48 | 1.84 | 1.27 | 3.52 | 6.44 | |
| Share holders equity per share | 1.48 | 1.84 | 1.27 | 3.53 | 6.44 | |
| Interest debt per share | 0 | 0 | 0 | 0.01 | 0.01 | |
| Market cap | 46.94M | 12.28M | 139.82M | 517.4M | 1.57B | |
| Enterprise value | 36.46M | -7.52M | 116.74M | 424.19M | 1.33B | |
| P/E ratio | -3.94 | -1.87 | -30.19 | -81.69 | -48.37 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -5.7 | -2.58 | -55.62 | -96.14 | -51.87 | |
| PFCF ratio | -5.7 | -2.58 | -55.22 | -90.33 | -29.89 | |
| P/B Ratio | 4.84 | 0.63 | 6.33 | 5.61 | 6.17 | |
| PTB ratio | 4.84 | 0.63 | 6.33 | 5.61 | 6.17 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -3.07 | 1.14 | -23.82 | -67.2 | -40.56 | |
| EV to operating cash flow | -4.43 | 1.58 | -46.43 | -78.82 | -44.15 | |
| EV to free cash flow | -4.43 | 1.58 | -46.1 | -74.06 | -25.44 | |
| Earnings yield | -0.25 | -0.53 | -0.03 | -0.01 | -0.02 | |
| Free cash flow yield | -0.18 | -0.39 | -0.02 | -0.01 | -0.03 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0.1 | 0.03 | 0.06 | 0.02 | 0.05 | |
| Net debt to EBITDA | 0.88 | 3 | 4.71 | 14.77 | 7.1 | |
| Current ratio | 9.42 | 39.22 | 16.83 | 50.4 | 19.51 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 0.69 | 0.73 | 0.54 | 0.85 | 0.93 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0.01 | 0.06 | 0.74 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | -0.31 | -15.73 | -41.6 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 7.8 | 5.04 | 2.76 | 4.39 | 10.92 | |
| ROIC | -1.23 | -0.34 | -0.22 | -0.07 | -0.13 | |
| Return on tangible assets | -1.1 | -0.33 | -0.2 | -0.07 | -0.12 | |
| Graham Net | 1.43 | 1.81 | 1.25 | 3.5 | 5.6 | |
| Working capital | 9.53M | 19.53M | 21.96M | 92.13M | 231.95M | |
| Tangible asset value | 0 | 0 | 0 | 0 | 0 | |
| Net current asset value | 9.53M | 19.53M | 21.96M | 91.89M | 231.62M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 667.5K | 602.5K | 682K | 911K | 4.02M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -1.23 | -0.33 | -0.21 | -0.07 | -0.13 | |
| Capex per share | 0 | 0 | 0 | -0.01 | -0.56 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.13 | -0.24 | -0.35 | -0.44 | -0.51 | |
| Operating cash flow per share | -0.13 | -0.37 | -0.2 | -0.59 | -0.54 | |
| Free cash flow per share | -0.13 | -0.92 | -0.2 | -0.6 | -0.57 | |
| Cash per share | 6.96 | 6.04 | 5.84 | 5.25 | 4.36 | |
| Book value per share | 6.92 | 6.7 | 6.35 | 5.93 | 4.96 | |
| Tangible book value per share | 6.92 | 6.67 | 6.35 | 5.91 | 4.94 | |
| Share holders equity per share | 6.92 | 6.7 | 6.35 | 5.93 | 4.96 | |
| Interest debt per share | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | |
| Market cap | 3.41B | 2.48B | 1.75B | 1.48B | 1.67B | |
| Enterprise value | 3.14B | 2.24B | 1.51B | 1.27B | 1.5B | |
| P/E ratio | -166.52 | -64.85 | -30.8 | -21.17 | -20.67 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -664.25 | -168.01 | -218.64 | -63.08 | -77.72 | |
| PFCF ratio | -654.95 | -67.4 | -215.93 | -61.96 | -73.76 | |
| P/B Ratio | 12.35 | 9.27 | 6.88 | 6.26 | 8.43 | |
| PTB ratio | 12.35 | 9.27 | 6.88 | 6.26 | 8.43 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -611.23 | -234.7 | -104.75 | -72.81 | -71.29 | |
| EV to operating cash flow | -610.16 | -151.67 | -189.44 | -54.17 | -69.62 | |
| EV to free cash flow | -601.61 | -60.84 | -187.1 | -53.21 | -66.08 | |
| Earnings yield | 0 | 0 | -0.01 | -0.01 | -0.01 | |
| Free cash flow yield | 0 | -0.01 | 0 | -0.02 | -0.01 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0.02 | 0.02 | 0.05 | 0.03 | 0.04 | |
| Net debt to EBITDA | 54.19 | 25.29 | 16.15 | 11.96 | 8.29 | |
| Current ratio | 60.29 | 39.82 | 19.51 | 32.73 | 22.06 | |
| Interest coverage | 0 | 0 | 0 | -574.87 | -24.31 | |
| Income quality | 1 | 1.54 | 0.56 | 1.34 | 1.06 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 1.49 | 0.01 | 0.02 | 0.05 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | -103.97 | -0.32 | -1.36 | -3.85 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 4.47 | 6 | 7.12 | 7.65 | 7.51 | |
| ROIC | -0.02 | -0.04 | -0.06 | -0.08 | -0.11 | |
| Return on tangible assets | -0.02 | -0.04 | -0.05 | -0.07 | -0.1 | |
| Graham Net | 6.84 | 5.88 | 5.52 | 5.07 | 4.15 | |
| Working capital | 274.92M | 245.59M | 231.95M | 215.41M | 174.96M | |
| Tangible asset value | 0 | 266.36M | 0 | 236.15M | 197.98M | |
| Net current asset value | 274.73M | 245.23M | 231.62M | 215.1M | 174.71M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 2.62M | 2.84M | 5.23M | 3.33M | 3.43M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.02 | -0.04 | -0.06 | -0.07 | -0.1 | |
| Capex per share | 0 | -0.55 | 0 | -0.01 | -0.03 |
SAVA Frequently Asked Questions
What is Cassava Sciences, Inc. stock symbol ?
Cassava Sciences, Inc. is a US stock , located in Austin of Tx and trading under the symbol SAVA
What is Cassava Sciences, Inc. stock quote today ?
Cassava Sciences, Inc. stock price is $30.92 today.
Is Cassava Sciences, Inc. stock public?
Yes, Cassava Sciences, Inc. is a publicly traded company.
Company Profile
- Volume Average 1.54M
- Market Capitalization 1.21B
- Employee 24
- CEO Mr. Remi Barbier
- Headquarters Austin,TX,US
- IPO Date 2000-07-14
-
Website
https://www.cassavasciences.com 
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
